Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

The present invention relates to a method for increasing the activity and/or the yield of a recombinant vitamin K-dependent protein expressed in cell culture. The present invention further relates to uses and compositions of matter.

Provided is a method for rapidly separating and extracting human umbilical cord mesenchymal stem cells (hUC-MSC). The method comprises the following steps: taking freshly collected healthy neonatal umbilical cord tissue, and after removing the blood vessels, bluntly dissecting the Wharton's jelly, mechanically pulverising same, and treating with erythrocyte lysate for 3 minutes; carrying out type IV collagenase digestion, and after sieving through a 100-200 mesh sieve, carrying out suspension culture in a serum-free culture medium, replacing the liquid every 3-5 days; taking the supernatant to detect cell contamination, and waiting for the adherence rate to reach 30-70%; carrying out trypsin digestion, collecting the cells by centrifugation, and carrying out passage amplification, until the rate of confluence of the cells reaches over 90%; collecting the cells for cryopreservation, and detecting the biological characteristics of the hUC-MSC.

A serum-free culture method for human umbilical cord mesenchymal stem cells (hUC-MSC), said method using a step-by-step method to culture hUC-MSC: first using a TME culture medium for culturing for 3-4 hours to promote hUC-MSC adherence, and then switching to a TMD culture medium for rapid amplification.

Provided is a serum-free culture medium, the ingredients of the culture medium comprising 0.05-0.2 parts by volume of -mercaptoethanol, 0.5-2 parts by volume of non-essential amino acid aqueous solution, 4-6 parts by volume of human mesenchymal stem cell culture supernatant concentrate, and 90-95 parts by volume of a-MEM/DMEM-F12 and recombinant human alkaline fibroblast growth factor of a final concentration of 5-5 ng/ml. The present culture medium is used for carrying out stem cell culture.

Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DC's) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DC's and Mphs with cancer cells are also disclosed herein.

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derided cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Disclosed herein are human trophoblast stem (hTS) cells, differentiated cells thereof, derivatives thereof such as cellular mass, and uses thereof. The isolation of hTS cells can express FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. The hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In the hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. The hTS cells could apply to human cell differentiation and for gene and cell-based therapies.

A method of producing a food ingredient is provided. The method comprising: (a) providing stem cells; and (b) culturing the stem cells in the presence of an affective amount of fatty acids or precursor thereof selected to reach an intracellular fatty acid profile of an edible species of interest which is not of the stem cells, so at to result in a food ingredient having a lipid organoleptic property of the edible species.

Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.